Altai Protocol Library
Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions
New Reference: Fixed-Duration Treatment of CLL
This phase 3 trial in untreated chronic lymphocytic leukemia patients showed that fixed-duration treatment with venetoclax combinations was noninferior to continuous ibrutinib in p
New Protocol: Durvalumab – Olaparib for Ovarina Cancer
This phase III DUO-O study in newly diagnosed advanced-stage ovarian cancer patients without tumor BRCA mutation showed that adding durvalumab plus olaparib to carboplatin/paclitax
New Indication: Datopotamab deruxtecan for Untreated Metastatic Triple-Negative Breast Cancer
This phase III trial demonstrated that datopotamab deruxtecan significantly improved progression-free and overall survival compared with chemotherapy in patients with previously un
New Protocol: Adjuvant Atezolizumab in dMMR Colon Cancer
In this phase 3 randomized trial, the addition of atezolizumab to mFOLFOX6 significantly improved 3-year disease-free survival compared to mFOLFOX6 alone in patients with resected
New Protocol: Cytarabine – MitoXANtrone – Venetoclax for Rel/Ref AML
The RELAX trial demonstrated that the combination of venetoclax with high-dose cytarabine and mitoxantrone is effective and safe for treating relapsed or refractory acute myeloid l
New Indication: Adjuvant Trastuzumab Deruxtecan for Residual Her2-Positive Breast Cancer
In this phase 3 trial, trastuzumab deruxtecan significantly improved invasive disease-free survival compared to trastuzumab emtansine in patients with residual HER2-positive early
New Reference: Tislelizumab with Chemotherapy for Nasopharyngeal Carcinoma
The RATIONALE-309 trial demonstrated that tislelizumab plus chemotherapy provided sustained progression-free survival and numerical overall survival improvements compared to placeb
New Protocol: Teclistamab with Daratumumab for Rel/Ref Multiple Myeloma
The study demonstrated significantly longer progression-free survival with teclistamab-daratumumab compared to DPd or DVd, with a hazard ratio of 0.17. The combination also achieve
New Drug: Pivekimab Sunirine for Blastic Plasmacytoid Dendritic Cell Neoplasm
Pivekimab Sunirine showed high response rates in patients with frontline de novo blastic plasmacytoid dendritic cell neoplasm, with a composite complete response rate of 75% and a
Our Solutions
Articles
Computerized Chemotherapy Order Entry
Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …
Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.